CCDC200: A Drug Target / Disease Biomarker (G100874261)

Target Name: CCDC200

NCBI ID: G100874261

CCDC200

CCDC200: A Drug Target / Disease Biomarker

CCDC200 is a protein that is expressed in various tissues throughout the body. It is a member of the carcinoembryonic antigen (CEA) family, which includes proteins that are expressed in a variety of tissues, including cancer cells. CCDC200 is also known as cancer-associated antigen (CAI), and it has been identified as a potential drug target for various diseases, including cancer.

CDC200 is a glycoprotein that is composed of a variable region and a constant region. The variable region of CDC200 consists of a unique transmembrane domain that is involved in the protein's localization and interactions with other proteins. The constant region of CDC200 includes a series of glycans that are involved in the protein's cell surface expression and interactions with other cells.

CDC200 has been shown to be involved in a variety of physiological processes in the body. For example, it has been shown to be involved in cell adhesion, migration, and invasion. It has also been shown to play a role in the development and progression of cancer.

One of the main potential uses of CDC200 as a drug target is its ability to promote the growth and survival of cancer cells. CCDC200 has been shown to stimulate the growth of cancer cells in a variety of contexts. For example, studies have shown that overexpression of CDC200 has been shown to promote the growth of breast cancer cells in a variety of contexts.

Another potential use of CDC200 as a drug target is its ability to inhibit the immune response. CCDC200 has been shown to stimulate the production of antibodies that are capable of recognizing and neutralizing foreign particles in the body. This can lead to an immune system that is less effective at fighting off infections and diseases.

CDC200 has also been shown to be involved in the development and progression of various cancers, including breast, ovarian, and prostate cancers. Studies have shown that CCDC200 is often overexpressed in these cancers, and that inhibiting its activity may be an effective way to treat these diseases.

In addition to its potential as a drug target, CCDC200 has also been shown to have potential as a biomarker. Studies have shown that CCDC200 can be used as a marker for various diseases, including cancer. For example, studies have shown that CCDC200 is often overexpressed in cancer cells, and that its levels can be used as a marker for the disease.

Overall, CCDC200 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments for the diseases that are associated with its activity.

Protein Name: Coiled-coil Domain Containing 200

The "CCDC200 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC200 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets